Abstract: Glaucoma is the name given to a group of diseases characterized by incurable, progressive, multifactorial optic neuropathy. It is the second leading cause of blindness worldwide. Ocular hypertension (OH) is the term used to describe the presence of raised intraocular pressure (the most important risk factor for the development of glaucoma) in the absence of demonstrable glaucomatous optic neuropathy. The management of glaucoma and OH requires a holistic and rational approach, taking into account a number of factors. Treatment needs to be individualized depending on patient age, the severity and type of glaucoma, associated medical conditions, the condition of the ocular surface, tolerability of topical medication, and patient wishes. An understanding of the mechanism of glaucoma and its etiology in a particular patient is crucial for the initiation of appropriate treatment. This review article summarizes the existing medical management of glaucoma and OH, including pharmacology, mode of action, and safety profile for each major group of medication, and reviews current advances and future developments in treatment for glaucoma, including experimental medications, together with a summary of their modes of action, pharmacology, and safety profiles. It is hoped that readers will become more aware of the evolution of the next generation glaucoma and OH medications.
Introduction
Glaucoma is the name given to a group of diseases characterized by incurable, progressive, multifactorial optic neuropathy. It is the second leading cause of blindness worldwide. [1] [2] [3] Ten percent of patients with glaucomatous optic nerve damage will suffer visual impairment and blindness 1 which is associated not only with increased morbidity but also with increased mortality. 2 Ocular hypertension (OH) is the term used to describe the presence of raised intraocular pressure (IOP, the most important risk factor for development of glaucoma) in the absence of demonstrable glaucomatous optic neuropathy.
Upon diagnosis, the management of glaucoma requires a holistic and rational approach, taking into account a number of factors. Treatment needs to be individualized depending on patient age, the severity and type of glaucoma, associated medical conditions, the condition of the ocular surface, tolerability of topical medication, and patient wishes. An understanding of the mechanism of glaucoma and its etiology in a particular patient is crucial for the initiation of appropriate treatment.
Published guidelines of the European Glaucoma Society 4 define the goal of glaucoma treatment as follows: "The preservation of visual function adequate to the individuals needs with minimal or no side effects, for the expected lifetime of the patient without any disruption of his/her normal activities at a sustainable cost." In the pursuit of this goal, the clinician may choose from four options, ie, no therapy, medical therapy, laser, and surgery. There are potentially three areas which can be targeted to delay or prevent progression of glaucoma. These are reduction of IOP, regulation of ocular blood flow, and neuroprotection. Currently, lowering of IOP is the only proven effective approach for preserving visual function 5, 6 and this is usually achieved initially with medical therapy. Over the past 30 years, the medical armamentarium has expanded greatly to include a number of efficacious and generally well tolerated medications. However, the search continues for safer and more effective products. This paper reviews the drugs currently in use before describing some of the novel agents in various stages of development and evaluation.
Case for Lowering IOP
Medical treatment has been shown in numerous studies to be beneficial in patients with glaucoma and OH. [7] [8] [9] [10] [11] [12] [13] [14] The Ocular Hypertension Treatment Study 15 showed that patients with OH on treatment who achieve a mean drop in IOP of 22% have a 4.4% risk of progression to glaucoma over five years compared with 9% without medication. This is an approximate 50% reduction in risk of progression to glaucoma with a 22% reduction in IOP. The inference from this study was that topical medication is effective in delaying or preventing the onset of glaucoma in patients with high IOP. This does not mean that all patients with borderline high IOP should receive medication. Only individuals who are at moderate or high risk of developing glaucoma should be treated. The study identified the following risk factors as being associated with increased risk of disease progression: older age, vertical and horizontal cup-to-disc ratios . 0.4-0.5, IOP . 26 mmHg and, importantly, a central corneal thickness , 555 µm. Treatment of OH should only be initiated if the risk of progression to sight-threatening glaucoma is assessed as outweighing the potential adverse effects of treatment with regard to the patient's quality of life. Lowering IOP in elderly patients or in those in whom the disease is very slowly progressive may not be necessary if the disease is unlikely to affect them during their lifetime.
Where glaucomatous neuropathy is already established, treatment is usually justifiable except where life expectancy is very limited. A number of landmark studies [7] [8] [9] [10] [11] [12] [13] [14] [15] suggested that, especially in advanced glaucoma, IOP reduction of at least 30% should be sought. However, with currently available drugs, this is often unachievable with a single medication and many patients therefore require use of multiple drops or fixed-combination treatments. The more drops patients have to use the less likely they are to be compliant with medication.
Current Treatment Options
The IOP-lowering efficacy and side effect profiles of currently available medications are summarized in Table 1 . It is clear that all of these treatments have shortcomings and that there is a need for better agents that target glaucoma more specifically and more potently without incurring adverse effects. A number of novel agents are now under development and evaluation. Some of these agents aim to improve IOP-lowering efficacy while minimizing the risk of adverse effects. The efficacy of a medication can be enhanced if it targets Reduces aqueous production. estimated to reduce iOP by 21%. 70 High rate of allergy, conjunctival hyperemia/blanching, follicular conjunctivitis (10%), subsensitivity, dry mouth, systemic blood pressure reduction (never use in children), fatigue and drowsiness, avoid with monoamine oxidase inhibitors (antidepressants) because it may cause serious systemic reactions. Prostamides (eg, bimatoprost) Increases aqueous outflow by the uveoscleral route. estimated to reduce iOP by 30%. 70 Conjunctival hyperemia, iris discoloration, bitter taste.
both aqueous production and outflow. Others aim to promote neuroprotection or improve optic nerve perfusion. Even methods of intervening in genetic mechanisms for some types of glaucoma are being explored.
A significant effort is being made to improve the existing classes of drugs. The aim is to decrease the side effects of some of the most successful drugs used in the treatment of glaucoma, namely prostaglandin analogs and prostamide. The most common side effects of this group of drugs are conjunctival hyperemia, increased iris pigmentation, and periorbital hyperpigmentation. These side effects could be prevented if a prostaglandin analog could be developed with selective activity towards the ciliary muscle cells to reduce IOP effectively whilst having no activity towards the conjunctival or iris blood vessel receptors, and thus preventing hyperemia. Prostamide has the advantage over latanoprost in this regard, with the incidence of hyperemia being 1% after two years compared with 30%, respectively. 16, 17 The following are the novel drugs which are currently being investigated for use in OH and glaucoma.
Drugs Under Investigation Prostaglandin FP receptor agonists
These are an addition to the numerous drops available but may not offer significant improvements over existing drugs. The mechanism of action exclusively involves pressure-independent increases in uveoscleral outflow (as shown in primate studies). 18 The following prostaglandin FP receptor agonists are currently being investigated.
18,19
Clinical Medicine Reviews in Therapeutics 2012:4 Prostaglandin eP2 receptor agonists These are useful in the treatment of OH and neurodegeneration associated with glaucoma. The mechanism of action is similar to that of prostaglandin FP receptor agonists as described above. 18 The patent for medical use of the prostaglandin EP2 receptor agonist is held by Allergan. The list of relevant patent applications relating to agents evaluated in this class is shown in Table 3 .
Prostaglandin eP4 receptor agonists
These are showing promise in lowering IOP, with effects demonstrated in nonhuman primates. The IOP is lowered by increasing the pressure-dependent outflow facility of the eye. 18 The mechanism of action of prostaglandin EP4 receptor agonists is different from that of other prostaglandin analogs. One of the early forms, ie, 3,7-dithia PGE 1 , lowers IOP by increasing the pressure-dependent outflow facility.
The following is a list of patent applications relating to agents evaluated in this class. (see Table 4 ).
Prostamides
Prostamides have been available since the turn of the 21st century, with bimatoprost being a prominent example of a synthetic analog of prostamide F2α. It has been shown to be more potent than prostaglandin FP receptor agonist prodrugs in reducing IOP, making it the most effective IOP-lowering agent of its kind. 20, 21 It can also be effective in patients whose response to latanoprost is poor. A number of new compounds in this drug class are currently being developed in the hope of out-performing bimatoprost.
22,23

Rho kinase inhibitors
Rho-associated coiled coil-forming protein kinase (ROCK) inhibitor has been shown to reduce IOP in Phase I clinical investigations. ROCK has been shown to be present in ocular tissues, including trabecular meshwork and ciliary muscles. Inhibition of ROCK activity has been shown to induce alterations in trabecular meshwork cellular responses, such as migration, adhesion, and changes in cell shape, which in turn improve aqueous outflow, thus reducing IOP. A Phase 1 clinical study showed that after topical ocular instillation of a ROCK inhibitor, the IOP-lowering effect was at its peak at 2-4 hours, after which the IOP gradually climbs back up to baseline. The safety profile of this experimental drug was good, with no reported systemic side effects. Local side effects are tolerable, most commonly mild hyperemia of the bulbar and palpebral conjunctiva. The following is a list of patent applications relating to agents in this class that have undergone evaluation. (see Table 5 ). 24 
Cannabinoids
Cannabinoids like marijuana (active ingredient tetrahydrocannabinol) have been demonstrated to lower IOP. 25, 26 However, due to the short half-life and myriad systemic side effects of marijuana, its development into useful IOP-lowering agents has not progressed. 27 Adverse effects are local redness and irritation and a Clinical Medicine Reviews in Therapeutics 2012:4 psychotropic effect. A number of different agents in this class have been the subjects of investigation and patent application as listed in Table 6 .
Serotonergics
The serotonin receptor (5HT 2 ) agonists have been shown to lower IOP in nonhuman primates. The exact mechanism of action has not been elucidated but it is thought that these modulate aqueous humor dynamics, thus lowering IOP. Many different potential drugs in this class have been under investigation. However, development of these is still in its infancy (Table 7) .
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Bioenergetic Therapies
This new area of research revolves around the theory that mitochondrial dysfunction can contribute towards neurodegeneration of retinal ganglion cells in glaucoma. This idea arises from the fact that similarities between glaucoma and mitochondrial optic neuropathies had previously been observed, with retinal ganglion cell loss being a common feature. Due to structural and energetic constraints, the retinal ganglion cell is susceptible to mitochondrial dysfunction. Age also plays a role in declining mitochondrial function. Early research has slowly opened up a new approach to slow down or halt glaucomatous neurodegeneration by finding ways to increase mitochondrial biogenesis or improving quality control in the mitochondrial life cycle.
29
RNA Nucleotides
New substances linked to the nervous system that innervate the eye are emerging as interesting candidates to reduce IOP. Nucleotides, commonly costored with catecholamines or acetylcholine or the indole, melatonin, show interesting properties in reducing IOP. Moreover, new technological ideas such as the use of small interference RNA to silence protein expression demonstrate the relevance of Nucleotides and dinucleotides of varying compounds exist in the aqueous humor of the eye. Depending on the compounds, some nucleotides increase IOP while others decrease it when administered topically. Those showing an IOP-reducing effect have been identified and studies are ongoing to assess and understand how these compounds can be developed into pharmaceutical agents. 30 Small interference RNA has been shown to prevent certain genes (depending on its targets) from expressing specific proteins. An animal experiment revealed that small interference RNAs against adrenergic receptors, acetylcholinesterase, and ATPases administered intravitreally can reduce IOP, which started to work after the third dose and having maximal effect at days 3-5. Intravitreal injection involving only small doses mean that systemic absorption is minimal, and hence systemic side effects are negligible. The downside is that the experimental route of administration is invasive. Studies are ongoing to devise a less invasive mode of administration, because this treatment approach is showing promise in view of its prolonged effects on IOP-lowering. 30 
Gene Therapy in Glaucoma
Gene mapping to find the cause of glaucoma and OH is ongoing, with regular updates in the various journals. With the passage of time, more and more genes are discovered to be associated with OH and glaucoma. As these genes are identified, biochemical mechanisms underlying the disease are being recognized, and new methods of therapy can be developed for management of OH and glaucoma. 31 
Neuroprotection
Reduction of IOP is the still the most common method of preventing progressive glaucomatous optic neuropathy, but clinical experience suggests it is only partly effective. Because glaucoma is a progressive neurodegenerative disease of the retinal ganglion cells and axons, neuroprotection could be an additional therapy to prevent progressive optic neuropathy.
Neuroprotection has been shown to be of benefit in other neurological conditions, such as Parkinson's disease, stroke, and Alzheimer's disease. Since glaucoma has in common with these conditions the mechanisms of neuronal injury of hypoxia, oxidative stress, and apoptosis, researchers have been prompted to consider whether neuroprotection may also have a potential role in the treatment of glaucoma. [32] [33] [34] In this context, a number of agents have been investigated, as follows.
Apoptosis inhibitors
Caspase-3 inhibition have been shown in animal glaucoma models to slow down the progression of retinal ganglion cell apoptosis. Furthermore, it has been shown that there are similarities in the mechanisms of molecular cell death between glaucoma and Alzheimer's disease, raising the possibility that neuroprotective strategies used in Alzheimer's disease may also have a role in treating human glaucoma. 35 Tumor necrosis factor alpha is a mediator of cellular apoptosis causing mitochondrial cell death by both caspase-dependent and caspase-independent pathways. GLC756, a dopamine receptor antagonist acting as a tumor necrosis factor alpha inhibitor in mast cells in rat model, 36, 37 is currently being investigated as a potential neuroprotectant.
Calpain in a calcium-dependent proteolytic enzyme which has been implicated in causing necrosis and apoptosis of ganglion cells. Several studies have shown the role of calpain in glaucoma 38 and hypoxic cell death.
39 SJA6017 (calpain inhibitors VI) and calpain 1 inhibitors protect retinal ganglion cells and are currently being studied for their role in OH and glaucoma. 40 
Neurotrophic factors
Neurotrophic factors, such as brain-derived neurotrophic factor, nerve growth factor, neurotrophins 3, 4 and 5, glial cell-derived neurotrophic factor, ciliary neurotrophic factor, and fibroblast growth factor-2, are some of the important neuromodulators and neurostimulants which are currently being studied for a potential role in the management of glaucoma and OH. 41 They selectively target TrkA 42 or TrkB 43 receptors in retinal ganglion cells and thus may offer protection to these cells.
Calcium channel blockers
Raised calcium is neurotoxic through activation of calcium-dependent catabolic enzymes. The exact mechanism of action of calcium channel blockers as neuroprotectants is unknown. The suggested to mechanisms of calcium channel blockers include direct action on calcium and improvement in ocular blood flow. Nifedipine, verapamil, and diltiazem have been shown to be effective in normal tension glaucoma 44, 45 and nilvadipine in open angle glaucoma. 46 Other calcium channel blockers, such as flunarizine and lomerizine, have shown to be effective in animal models but not in humans. 47 Calcium channel blockers should be used with caution because of their systemic hypotensive effect which may be potentially detrimental to optic nerve head perfusion. 48 
Free radical scavengers and antioxidants
Several free radical scavengers are currently being studied for their role as neuroprotectants. Coenzyme Q10 have yet been studied as a neuroprotectant in animals. No human trials have yet been conducted to date. [49] [50] [51] Several mechanisms of action have been proposed, such as an action on the mitochondrial transport chain, thereby producing energy to overcome the effect of excessive glutamate, inhibition of inflammatory and autoimmune factors, such as NF-κB, and also acting as a free radical scavenger. Coenzyme Q10 prevents oxidative damage to cells and thus protects retinal ganglion cells.
Vitamin E (alpha tocopherol) is a lipid-soluble vitamin which acts as an antioxidant in cells. Small studies have shown a protective effect in retinal cells by direct vasoregulatory and protein kinase C-mediated glutamate transport activity. 52, 53 These results are very much in the initial stages and no concrete data are available.
Melatonin
Melatonin is a neurohormone produced by the pineal gland and is a regulator of circadian rhythm. Its concentration in aqueous humor fluctuates and is highest at night time. Several studies have correlated diurnal changes in IOP with fluctuation in melatonin levels, and suggested that a melatoninergic mechanism is involved in the circadian rhythm of IOP. Oral administration of melatonin has been shown to reduce IOP in humans, and topical administration of melatonin has shown a similar IOP-lowering effect in animal models, with the effect lasting as long as nine hours in rabbits and 18 hours in monkeys. The mechanisms of action of melatonin and its analogs are not clearly elucidated to date, but studies are ongoing to produce a clearer idea of its mechanisms of action and how best to harness it as a pharmaceutical agent to reduce IOP in OH and glaucoma. 30 
Ginkgo biloba
Ginkgo biloba (EGb 761) is a platelet-activating factor which acts as an antioxidant, free radical scavenger, glutamate NMDA receptor inhibitor and nitric oxide inhibitor to increase the survival of retinal ganglion cells. 54, 55 It should be avoided in patient already on some antiplatelet agent such as aspirin to decrease the risk of bleeding. Although evidence to support its use is very limited 56, 57 some ophthalmologists employ it in the treatment of cases of advanced glaucoma.
Nitric oxide synthase inhibitor
Nitric oxide synthase 2 is present in astrocytes in optic nerve heads from glaucomatous human eyes, but not in normal eyes. It has been postulated that nitric oxide synthase 2 is one of the key players in inducing apoptosis of retinal ganglion cells in glaucoma. Aminoguanidine inhibition of nitric oxide synthase 2 has been shown to delay retinal ganglion cell loss in animal glaucoma model, without any effect on IOP. Aminoguanidine was administered in the animals' drinking water. There were no significant systemic side effects reported. 58 
NMDA receptor antagonists
Memantine (1-amino-3,5-dimethyladamantane) is an NMDA glutamate receptor antagonist approved as a neuroprotectant in Alzheimer's dementia. It has been shown to reduce functional loss of vision associated with monkey experimental glaucoma safely and effectively, although it has no IOP-lowering effects. This was achieved by orally administering memantine to the monkeys. There were no systemic adverse reactions noted. 59, 60 Despite the promise of these early studies, a potential role for memantine remains uncertain. Two parallel double-blind trials have been conducted with memantine in humans using different doses. One of the studies showed slower rate of progression Clinical Medicine Reviews in Therapeutics 2012:4 of glaucoma with higher doses of memantine but the second study showed no significant difference in visual field progression between treated and placebo group. As a consequence, there was no basis for the approval of memantine for use in glaucoma. 61 Flupirtine, a tricyclic antidepressant, especially when combined with interferon-β act as a neuroprotectant in animal studies. No human trial has been done until now. No human trial has yet been carried out.
Riluzole 62 and dextromethorphan 63 are two other NMDA antagonists with neuroprotectant activity.
immune mediators
Glatiramer acetate, an immune mediator, is a synthetic oligopeptide used in multiple sclerosis, have been shown to increase survival of retinal ganglion cells in animals. Geranylgeranylacetone, an acyclic polyisoprenoid, and amyloid beta antibody are two other immune mediators in which neuroprotectant activity has been demonstrated.
ephrins
Ephrins act as axonal guidance molecules and their levels have been shown to rise in central nervous system injuries in adults (which also include nerve layer damage from raised IOP). They are seen both as inhibitors of regrowth of regenerating axons as well as stimulating astrocyte activation and gliosis. This means that the damaged axons do not degenerate, and in addition, glial scar formation acts as a seal to the site of injury to provide a physical barrier to neuronal degeneration. Therefore, it is postulated that the inhibition of ephrins may offer a new strategy in preventing effects of neurodegeneration in the retina secondary to raised IOP. [64] [65] [66] Heat shock proteins Heat shock proteins are groups of different proteins expressed as a reaction to cell stress. These proteins enhance survivability of cells exposed to what would otherwise be a lethal stress. Among the protein groups, only heat shock protein 27 can protect dorsal root ganglion neurons from apoptosis induced by nerve growth factor withdrawal. Therefore, heat shock protein 27 has been investigated to determine if it has a similar protective effect on retinal ganglion cells which are put under stress. Heat shock protein 27 applied to the retinal ganglion cells in animal glaucoma models resulted in increased resistance to apoptosis induced by ischemia-reperfusion injury. This forms a basis for further studies into its role in neuroprotection in eyes with raised IOP. Currently the need for invasive administration is a major obstacle. No adverse systemic reactions were reported. 67 
Glutamate
Release of glutamate has been implicated as a mechanism of retinal ganglion cell death/degeneration in glaucoma. It has been demonstrated that glutamate plays a pivotal role in the induction of apoptosis of retinal ganglion cells in retinal damage, caused among other things, raised IOP. Glutamate-modulating agents were administered intravitreally into eyes with experimentally raised IOP in an animal model, with a reduction in the apoptosis rate in retinal ganglion cells. There were no reports of adverse systemic reactions in this study. The modulation of glutamate release has thus been demonstrated to be a viable potential neuroprotective strategy in glaucoma-related animal models. The requirement for intravitreal drug delivery may again be considered a significant obstacle and more development is needed to make this an effective non-invasive drug strategy for future use. 68 
Sulfhydryl
Sulfhydryl is a naturally occurring organic sulfur molecule that can influence enzymatic activities in proteins of living beings. Activated, it can induce apoptosis. Therefore, tris(2-carboxyethyl) phosphine, a sulfhydryl reductant which does not contain oxidizable sulfhydryls, injected intravitreally has been shown in animal models to confer a neuroprotective effect for retinal ganglion cells. No toxic effect of retinal ganglion cell survival was observed, and no syssystemic side effects were noted. Once again, the need for invasive administration presents a significant difficulty and more studies are required to improve our understanding of the underlying mechanism of action of this approach and to devise a less invasive method of effectively administering this agent.
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Lastly, patient compliance is of paramount importance to ensure sustained control of IOP. Poor compliance can be partly due to the discomfort in using the medications. Newer, less irritable IOP lowering agents are being developed for better patient comfort, as this will increase compliance among patients.
Summary
A small summary can be drawn from the research into neuroprotection as a different approach in managing OH and glaucoma, in that it utilizes the idea of inhibiting the many identified factors that promote apoptosis of retinal ganglion cells to preserve functional vision, with or without consideration of IOP-lowering. Although this approach is laudable, more studies are needed to look for new modifiable factors that can trigger retinal ganglion cell apoptosis under conditions of raised IOP. This will then allow for a more concerted effort in targeting and inhibiting major factors contributing to the apoptotic process in OH and glaucoma. In conclusion, the search continues for improved treatments for ocular hypertension and glaucoma. We can be optimistic that some of the agents currently under investigation may progress successfully through clinical trials to provide the clinician with safer and more effective weapons in the fight against glaucomainduced blindness.
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